Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models
10.4196/kjpp.2019.23.5.329
- Author:
Dae Hwan NAM
1
;
Jinsook PARK
;
Sun Hyun PARK
;
Ki Suk KIM
;
Eun Bok BAEK
Author Information
1. Predictive Model Research Center, Korea Institute of Toxicology, Daejeon 34114, Korea. baekeunbok@hanmail.net
- Publication Type:Original Article
- Keywords:
Dipeptidyl peptidase-IV;
Gemigliptin;
Myocardial ischemia-reperfusion injury;
Pressure-volume loop;
Spontaneously hypertensive rat
- MeSH:
Animals;
Blood Glucose;
Hemodynamics;
Hypertension;
Hypertrophy;
Models, Animal;
Rats;
Rats, Inbred SHR;
Rats, Sprague-Dawley
- From:The Korean Journal of Physiology and Pharmacology
2019;23(5):329-334
- CountryRepublic of Korea
- Language:English
-
Abstract:
Diabetes is associated with an increased risk of cardiovascular complications. Dipeptidyl peptidase-4 (DPP-IV) inhibitors are used clinically to reduce high blood glucose levels as an antidiabetic agent. However, the effect of the DPP-IV inhibitor gemigliptin on ischemia/reperfusion (I/R)-induced myocardial injury and hypertension is unknown. In this study, we assessed the effects and mechanisms of gemigliptin in rat models of myocardial I/R injury and spontaneous hypertension. Gemigliptin (20 and 100 mg/kg/d) or vehicle was administered intragastrically to Sprague-Dawley rats for 4 weeks before induction of I/R injury. Gemigliptin exerted a preventive effect on I/R injury by improving hemodynamic function and reducing infarct size compared to the vehicle control group. Moreover, administration of gemigliptin (0.03% and 0.15%) powder in food for 4 weeks reversed hypertrophy and improved diastolic function in spontaneously hypertensive rats. We report here a novel effect of the gemigliptin on I/R injury and hypertension.
